

# Andrea Sartore-Bianchi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7554181/andrea-sartore-bianchi-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

164  
papers

19,751  
citations

48  
h-index

140  
g-index

198  
ext. papers

23,290  
ext. citations

8.9  
avg, IF

6.08  
L-index

#	Paper	IF	Citations
164	The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 104, 102351	14.4	3
163	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.. <i>Oncologist</i> , <b>2022</b> , 27, e29-e36	5.7	0
162	Efficacy of retreatment with oxaliplatin-based regimens in metastatic colorectal cancer patients: The RETROX-CRC retrospective study.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 127-127	2.2	
161	Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients.. <i>European Journal of Cancer</i> , <b>2022</b> ,	7.5	0
160	ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2200015	3.6	2
159	Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.. <i>European Journal of Cancer</i> , <b>2021</b> , 163, 16-25	7.5	3
158	Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management.. <i>ESMO Open</i> , <b>2021</b> , 7, 100338	6	2
157	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , <b>2021</b> , 24, 897-912	7.6	1
156	Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ. <i>Nature Communications</i> , <b>2021</b> , 12, 2340	17.4	6
155	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. <i>Cancer Discovery</i> , <b>2021</b> , 11, 1923-1937	24.4	10
154	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3506-3506	2.2	21
153	Clonally expanded EOMES Tr1-like cells in primary and metastatic tumors are associated with disease progression. <i>Nature Immunology</i> , <b>2021</b> , 22, 735-745	19.1	10
152	Liquid Biopsy for Small Cell Lung Cancer either De Novo or Transformed: Systematic Review of Different Applications and Meta-Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
151	Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 779-789	21.7	53
150	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
149	Strategies to tackle RAS-mutated metastatic colorectal cancer. <i>ESMO Open</i> , <b>2021</b> , 6, 100156	6	7
148	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , <b>2021</b> , 5,	3.6	1

147	The Evolutionary Landscape of Treatment for Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	12
146	Optimized EGFR Blockade Strategies in Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 3126-3140	12.9	6
145	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2505-2514	12.9	3
144	Liquid Biopsy for Prognosis and Treatment in Metastatic Colorectal Cancer: Circulating Tumor Cells vs Circulating Tumor DNA. <i>Targeted Oncology</i> , <b>2021</b> , 16, 309-324	5	2
143	The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 403-409	8.7	22
142	The Quest for Improving Treatment of Cancer of Unknown Primary (CUP) Through Molecularly-Driven Treatments: A Systematic Review. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 533	5.3	11
141	Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer: Long-term Results of Treatment With Trastuzumab and Lapatinib. <i>JAMA Oncology</i> , <b>2020</b> , 6, 927-929	13.4	9
140	Entrectinib for the treatment of metastatic NSCLC: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , <b>2020</b> , 20, 333-341	3.5	16
139	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 256-262.e2	3.8	22
138	Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study. <i>European Journal of Cancer</i> , <b>2020</b> , 135, 230-239	7.5	6
137	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1017-1024	12.9	8
136	Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. <i>European Radiology Experimental</i> , <b>2020</b> , 4, 62	4.5	14
135	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS4124-TPS4124	2.2	6
134	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1372-1384	12.9	38
133	Breaking Barriers in HER2+ Cancers. <i>Cancer Cell</i> , <b>2020</b> , 38, 317-319	24.3	3
132	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , <b>2020</b> , 5, e000911	6	35
131	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1135-1147	10.3	27
130	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 91, 102112	14.4	8

129	Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 3215-3223	7.5	7
128	CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	14
127	Liquid biopsy for rectal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 79, 101893	14.4	17
126	Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3099-3110	2.2	35
125	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits. <i>Cancer Research</i> , <b>2019</b> , 79, 5884-5896	10.1	26
124	Increased incidence of colon cancer among individuals younger than 50 years: A 17 years analysis from the cancer registry of the municipality of Milan, Italy. <i>Cancer Epidemiology</i> , <b>2019</b> , 60, 134-140	2.8	24
123	Combined Low Densities of FoxP3 and CD3 Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression. <i>Cancer Immunology Research</i> , <b>2019</b> , 7, 751-758	12.5	19
122	The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1510-1511	13.4	0
121	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6243-6259	12.9	25
120	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. <i>European Journal of Cancer</i> , <b>2019</b> , 118, 121-130	7.5	29
119	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 622	5.3	17
118	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , <b>2019</b> , 79, 1375-1394	12.1	29
117	Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1268-1275	13.4	37
116	Adaptive mutability of colorectal cancers in response to targeted therapies. <i>Science</i> , <b>2019</b> , 366, 1473-1480	9.3	148
115	A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3509-3509	2.2	1
114	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS2659-TPS2659	2.2	8
113	Mutational signatures of early-onset colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15113-e15113	15.1	13
112	Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e15086-e15086	2.2	

111	Plasma HER2 ( ) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3046-3053	12.9	58
110	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , <b>2019</b> , 24, 1395-1402	5.7	45
109	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , <b>2019</b> , 4,	6	12
108	Concurrent Small-Cell Transformation and Emergence of -C797S and T790M Mutations Under Sequential Treatment With EGFR Inhibitors in Lung Adenocarcinoma.. <i>JCO Precision Oncology</i> , <b>2019</b> , 3, 1-5	3.6	2
107	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 73, 41-53	14.4	44
106	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e117-e129	3.8	32
105	Early-onset colorectal cancer in young individuals. <i>Molecular Oncology</i> , <b>2019</b> , 13, 109-131	7.9	173
104	Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer. <i>Handbook of Experimental Pharmacology</i> , <b>2018</b> , 249, 145-159	3.2	1
103	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 1108-1119	10.3	101
102	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. <i>ESMO Open</i> , <b>2018</b> , 3, e000299	6	24
101	Lipid-lowering therapy of everolimus-related severe hypertriglyceridaemia in a pancreatic neuroendocrine tumour (pNET). <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2018</b> , 43, 114-116	2.2	1
100	Human Epidermal Growth Factor Receptor 2 as a Molecular Biomarker for Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , <b>2018</b> , 4, 19-20	13.4	14
99	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 119-126	10.3	46
98	Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2018</b> , 29, 2143-2144.3	6	6
97	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , <b>2018</b> , 34, 148-162.e7	24.3	77
96	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. <i>Nature Communications</i> , <b>2018</b> , 9, 2287	17.4	14
95	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. <i>Gut</i> , <b>2018</b> , 67, 1995-2005	19.2	119
94	First-line FOLFOX plus panitumumab (Pan) followed by 5FU/LV plus Pan or single-agent Pan as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3505-3505	2.2	20

93	Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3506-3506	2.2	6
92	Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 581-581	2.2	1
91	Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the BRAF, BeCool platform.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 639-639	2.2	2
90	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 80-83	3.8	34
89	TRKA expression and gene copy number across solid tumours. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 926-931	3.9	9
88	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 3657-3666 <sup>12.9</sup>	12.9	44
87	Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, e153-e163	3.8	70
86	Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer Discovery</i> , <b>2017</b> , 7, 400-409	24.4	475
85	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	126
84	Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. <i>Annals of Oncology</i> , <b>2017</b> , 28, 1302-1308	10.3	23
83	Molecular Markers Beyond Microsatellite Instability for Assessing Prognosis in Early-Stage Colorectal Cancer: What Happens at Relapse?. <i>JAMA Oncology</i> , <b>2017</b> , 3, 481-482	13.4	1
82	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. <i>European Journal of Cancer</i> , <b>2017</b> , 71, 43-50	7.5	22
81	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , <b>2017</b> , 552, 116-120	50.4	290
80	Pooled Analysis of Clinical Outcome of Patients with Chemorefractory Metastatic Colorectal Cancer Treated within Phase I/II Clinical Studies Based on Individual Biomarkers of Susceptibility: A Single-Institution Experience. <i>Targeted Oncology</i> , <b>2017</b> , 12, 525-533	5	11
79	Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer <b>2017</b> ,		16
78	Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 158-62	2.3	22
77	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 51, 54-62	14.4	19
76	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , <b>2016</b> , 76, 4504-15	10.1	63

75	Linitis Plastica of the Rectum As a Clinical Presentation of Metastatic Lobular Carcinoma of the Breast. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e54-6	2.2	9
74	Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. <i>Clinical Colorectal Cancer</i> , <b>2016</b> , 15, 213-21	3.8	23
73	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1062-1067	10.3	28
72	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 147-153	24.4	255
71	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. <i>Cancer Discovery</i> , <b>2016</b> , 6, 36-44	24.4	200
70	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	94
69	Abstract CT082: Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial <b>2016</b> ,		3
68	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS774-TPS774	2.2	16
67	The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS3636-TPS3636	2.2	
66	gene fusions as novel targets of cancer therapy across multiple tumour types. <i>ESMO Open</i> , <b>2016</b> , 1, e000023	2.2	289
65	Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). <i>ESMO Open</i> , <b>2016</b> , 1, e000111	6	22
64	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. <i>Nature Communications</i> , <b>2016</b> , 7, 13665	17.4	121
63	Clonal evolution and -coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. <i>ESMO Open</i> , <b>2016</b> , 1, e000079	6	2
62	Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1456-66	10.3	31
61	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 738-746	21.7	533
60	BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2092-7	10.3	110
59	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1994-1999	18.3	93
58	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. <i>Nature Communications</i> , <b>2015</b> , 6, 7002	17.4	178

57	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , <b>2015</b> , 526, 263-7	50.4	310
56	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , <b>2015</b> , 28, 1481-91	9.8	144
55	Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function. <i>International Journal of Biological Markers</i> , <b>2015</b> , 30, e275-81	2.8	3
54	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , <b>2015</b> , 21, 795-801	50.5	557
53	Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 1730-4	8.7	57
52	Alka-372-001: First-in-human, phase I study of entrectinib [an oral pan-trk, ROS1, and ALK inhibitor] in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2517-2517	2.2	20
51	Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3508-3508	2.2	23
50	Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 565-565	2.2	2
49	Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 583-583	2.2	1
48	Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , <b>2015</b> , 6, 31604-12	3.3	27
47	The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. <i>Molecular Oncology</i> , <b>2014</b> , 8, 1495-507	7.9	101
46	Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106, djt322	9.7	58
45	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1269-80	24.4	326
44	Regorafenib in metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , <b>2014</b> , 14, 255-65	3.5	16
43	Detection of circulating tumor DNA in early- and late-stage human malignancies. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra24	17.5	2741
42	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 224ra26	17.5	203
41	Acquired resistance to EGFR-targeted therapies in colorectal cancer. <i>Molecular Oncology</i> , <b>2014</b> , 8, 1084-94	9.9	94
40	Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2502-2502	2.2	17



39	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. <i>International Journal of Cancer</i> , <b>2013</b> , 133, 1259-65	7.5	141
38	Regorafenib for metastatic colorectal cancer. <i>Lancet, The</i> , <b>2013</b> , 381, 1537	4.0	14
37	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study. <i>Cancer</i> , <b>2013</b> , 119, 3429-35	6.4	23
36	Magnetic resonance imaging as an early indicator of clinical outcome in patients with metastatic colorectal carcinoma treated with cetuximab or panitumumab. <i>Clinical Colorectal Cancer</i> , <b>2013</b> , 12, 45-53 <sup>3.8</sup>	3.8	12
35	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. <i>Cancer Discovery</i> , <b>2013</b> , 3, 658-73	24.4	489
34	Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 2265-72	12.9	85
33	Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e62264	3.7	18
32	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectal Cancer Enhanced Stratification).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS3648-TPS3648	2.2	7
31	Aspirin for colorectal cancer with PIK3CA mutations: the rising of the oldest targeted therapy?. <i>Annals of Translational Medicine</i> , <b>2013</b> , 1, 12	3.2	4
30	Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. <i>Current Colorectal Cancer Reports</i> , <b>2012</b> , 8, 272-276	1	1
29	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , <b>2012</b> , 486, 532-6	50.4	1327
28	Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study. <i>Journal of Clinical Pathology</i> , <b>2012</b> , 65, 218-23	3.9	29
27	A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 508-23	24.4	668
26	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 1812-20	27.4	580
25	Response: Re: Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , <b>2010</b> , 102, 573-575	9.7	0
24	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2010</b> , 36 Suppl 3, S1-5	14.4	32
23	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 753-62	21.7	1653
22	Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. <i>Targeted Oncology</i> , <b>2010</b> , 5, 19-28	5	26

21	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. <i>PLoS ONE</i> , <b>2009</b> , 4, e7287	3.7	209
20	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. <i>Cancer Research</i> , <b>2009</b> , 69, 1851-7	10.1	642
19	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 1308-24	9.7	424
18	EGFR FISH in colorectal cancer: what is the current reality?. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 402-3	21.7	38
17	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5705-12	2.2	1358
16	Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 4217-9	2.2	191
15	Controversial evaluation of EGFR protein and gene status in predicting response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer: a case report and review of the literature. <i>Targeted Oncology</i> , <b>2008</b> , 3, 127-130	5	4
14	Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 5942-51	12.9	81
13	Epidermal Growth Factor Receptor-Targeted Therapy of Colorectal Cancer with Panitumumab. <i>Current Cancer Therapy Reviews</i> , <b>2007</b> , 3, 249-254	0.4	
12	Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3238-45	2.2	293
11	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. <i>Cancer Research</i> , <b>2007</b> , 67, 2643-8	10.1	708
10	Cetuximab for treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 7, vii66-7	10.3	9
9	Anti-EGFR monoclonal antibodies in the treatment of non-small cell lung cancer. <i>Annals of Oncology</i> , <b>2006</b> , 17 Suppl 2, ii49-51	10.3	4
8	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. <i>Lancet Oncology, The</i> , <b>2005</b> , 6, 279-86	21.7	833
7	Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. <i>Lung Cancer</i> , <b>2005</b> , 48, 429-34	5.9	47
6	Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1848-9	10.3	23
5	Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients. <i>Oncology Reports</i> , <b>2005</b> , 13, 689-95	3.5	5
4	Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. <i>Cancer</i> , <b>2004</b> , 100, 2132-8	6.4	21

3	Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients. <i>Oncology Reports</i> , <b>2004</b> , 12, 855-9	3.5	2
2	Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?. <i>Lung Cancer</i> , <b>2002</b> , 38, 159-62	5.9	6
1	Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation. <i>Journal of Clinical Oncology</i> , <b>2000</b> , 18, 3319-20	2.2	16